DermBiont is a clinical-stage biotechnology company dedicated to developing targeted topical therapeutics for skin diseases. With multiple active Investigational New Drug applications (INDs) and ongoing Phase 2 clinical trials, DermBiont is advancing promising treatments for conditions such as seborrheic keratosis and hyperpigmentation disorders. The company seeks to address the root causes of skin diseases through first-in-class therapeutics that leverage precise mechanisms of action. DermBiont's commitment to excellence is demonstrated by its focus on efficient clinical trials and regulatory strategies, supported by a team with extensive industry experience. The company fosters an empowering environment that encourages its employees to excel in their roles while contributing to the advancement of dermatological science.